NICE Assessment Outcomes

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

Patients in England suffering from severe beta-thalassaemia will soon have access to a groundbreaking one-time gene therapy,...

NICE Endorses Almirall's Ebglyss for Treating Moderate to Severe Atopic Dermatitis | iPharmaCenter

New Systemic Treatment Option Recommended for Patients Aged 12 and Over The National Institute for Health and Care Excellence (NICE) has...

NICE Recommends Relugolix for Advanced Prostate Cancer Treatment

Innovative Oral Therapy Approved for Over 40,000 Patients The National Institute for Health and Care Excellence (NICE) in the UK has...

Hemgenix Receives Managed Access Recommendation for Treating Severe Haemophilia B in Adults | iPharmaCenter

CSL Behring's Hemgenix has been recommended for managed access as a treatment option for adults with moderately severe or severe...

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

Keytruda (pembrolizumab) combined with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy is not recommended for initial...

Servier Laboratories' Tibsovo Combined with Azacitidine Recommended by NICE for Adult Patients with Newly Diagnosed AML with IDH1 Mutation | iPharmaCenter

Ivosidenib Plus Azacitidine Endorsed by NICE for Treating Acute Myeloid Leukaemia in Adults Ineligible for Standard Induction...

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

Aquipta, recommended by NICE, presents a new option for preventing migraines in adults with at least 4 migraine days monthly after at...

NICE recommended the use of AI-derived solutions to detect stroke | iPharmaCenter

NICE announced that artificial intelligence (AI)-derived solutions are available for implementation within the NHS as further evidence is...

January 10, 2024 NICE recommended Alexion's Kanuma for LAL deficiency Sebelipase alfa, marketed as Kanuma by Alexion, holds an indication...

NICE ASSESSMENT OUTCOMES | 2023 | (2/N) | UK HEALTHCARE NEWS | IPHARMACENTER

Camzyos (mavacamten) has been recommended as a viable option for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in...

Yescarta has been recommended for adults with diffuse large B-cell lymphoma (DLBCL) after one treatment and is currently indicated as the...

December 15, 2022 SOBI's Doptelet was recommended for treating refractory primary chronic immune thrombocytopenia. NICE recommended using...